体重指数大于30患者中米索前列醇最佳给药剂量:一项随机对照试验
该双盲实用性随机对照试验纳入180例体重指数≥30 kg/m²的引产患者,比较阴道米索前列醇25 μg与50 μg从引产开始至分娩的时间。总体两组分娩时间无显著差异(21.6小时 vs 18.6小时;d=0.28;95%CI -0.02至0.57),但计划亚组分析中经产妇50 μg组分娩时间显著缩短(15.2小时 vs 12.0小时;d=0.51;95%CI 0.04-0.97)。
要点
- 肥胖患者阴道米索前列醇50 μg与25 μg总体分娩时间无显著差异。
- 经产妇亚组中50 μg组分娩时间显著短于25 μg组。
- 伴胎心监护变化的子宫过频收缩总体罕见(2.2%),两组无显著差异。
核心结论
- 肥胖患者使用50 μg与25 μg阴道米索前列醇促宫颈成熟的分娩时间相似,但经产妇使用50 μg时分娩时间显著缩短,更高剂量可能是缩短产程的有前景干预措施,值得进一步研究。
研究设计与样本
- 双盲实用性随机对照试验,于2022年6月1日至2023年7月17日开展。
- 纳入体重指数≥30 kg/m²、≥36周妊娠、单胎、入院时宫颈扩张≤3 cm的行引产患者,排除阴道分娩或米索前列醇禁忌者。
- 随机分配至阴道米索前列醇25 μg或50 μg组,按产次、体重指数<40 kg/m²或≥40 kg/m²及提供者引产开始时计划机械扩张分层。
- 预先估算每组90例(N=180)以85%把握度检测组间3小时差异,I型错误5%,采用意向性分析。
- 主要结局为从引产至分娩的时间,使用两样本t检验,Cohen's d作为效应量,报告P值。
主要发现
- 随机化180例中,25 μg组88例,50 μg组92例,96.1%患者接受了指定干预,基线特征相似。
- 主要结局分娩时间无差异(21.6小时 vs 18.6小时;d=0.28;95%CI -0.02至0.57)。
- 计划亚组分析中经产妇50 μg组分娩更快(15.2小时 vs 12.0小时;d=0.51;95%CI 0.04-0.97)。
- 伴胎心监护变化的子宫过频收缩总体罕见(2.2%),两组无显著差异,母儿不良反应无差异。
临床怎么用
- 作者认为,更高剂量米索前列醇可能是缩短产程的有前景干预措施,值得进一步研究。
局限性
- 原文结论指出更高剂量米索前列醇可能是缩短产程的有前景干预措施,值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with obesity experience an increased duration of labor with an increased risk for perinatal morbidity. When compared with parturients without obesity, they also experience fewer uterine contractions after administration of misoprostol. It is unclear if the same dose of misoprostol should be used for induction of labor in patients with obesity compared to non-obese patients. Therefore, we sought to investigate if a higher dose of misoprostol for patients with obesity is more effective. OBJECTIVE: This study aimed to determine if 50 μg compared with 25 μg of vaginal misoprostol reduced the time from induction start to delivery among patients with obesity. STUDY DESIGN: We performed a double-blinded, pragmatic randomized controlled trial, between June 1, 2022, and July 17, 2023. Patients with a body mass index ≥30 kg/m2 who underwent labor induction at ≥ 36 weeks' gestation, had a singleton gestation, and a cervical dilation ≤3 cm at admission were included. Patients were excluded if they had a contraindication to vaginal delivery or misoprostol administration. Patients were randomized to 25 or 50 μg of vaginal misoprostol, stratified by parity, body mass index <40 kg/m2 or ≥40 kg/m2, and provider intent to use mechanical dilation at the onset of labor induction. Usual labor management was followed at the discretion of the provider. The primary outcome was time from induction to delivery. A priori, we estimated that 90 subjects per group (N=180) were needed for an 85% power to detect a 3-hour difference between groups with a type I error of 5%. Analysis was by intention-to-treat. A 2-sample t test was used for the primary outcome, Cohen's d was used as a measure of effect, and P values were reported. RESULTS: Of the 180 patients randomized, 88 were assigned to the 25 μg group and 92 were assigned to the 50 μg group. Of those, 96.1% of patients received the designated intervention. The baseline characteristics were similar between groups. No difference was found in the primary outcome of time to delivery (21.6 hours vs 18.6 hours; d=.28; 95% confidence interval, -0.02 to 0.57). In a planned subgroup analysis, multiparous patients delivered faster in the 50 μg group (15.2 hours vs 12.0 hours; d=.51; 95% confidence interval, 0.04-0.97). The risk for tachysystole associated with fetal heart tracing changes was rare overall (2.2%) and not significantly different between groups. No differences in maternal or neonatal adverse effects were observed. CONCLUSION: Patients with obesity who underwent cervical ripening with 50 μg of vaginal misoprostol experienced a similar time to delivery when compared with those who received 25 μg of misoprostol. However, multiparous patients had a significantly reduced time to delivery when 50 μg was used. A higher dose of misoprostol may be a promising intervention for reducing time in labor, which warrants further study.
引用
- Saucedo AM, Alvarez M, Macones GA, et al. Optimal misoprostol dosing among patients with a body mass index greater than 30: a randomized controlled trial. Am J Obstet Gynecol. 2024. PMID: 38367750. doi:10.1016/j.ajog.2024.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。